Crawford resigns from FDA

Share this article:
Lester Crawford resigned today from his position as commissioner of the FDA.
In an internal memo to all staff, obtained by MM&M, Crawford wrote, "After three and a half years as Deputy Commissioner, Acting Commissioner and, finally, as Commissioner, it is time at the age of 67, to step aside. I am doing so with deep gratitude to the President and both Secretaries of Health and Human Services for whom I have been privileged to serve.
"I also must thank the extraordinary people of FDA for the honor of having served with them a fourth time over a 30 year period. They have made public service a joy and a pleasure as we worked together to accomplish great things for public health. Certainly, the Critical Path Initiative, the Drug Safety Program, the three user fee acts passed since 2002, and the various good manufacturing practice reforms will continue to make a difference in the lives of all Americans."
Crawford was confirmed as commissioner in July.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...